Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

https://escholarship.org/uc/item/3k76b3nf
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

BACKGROUND AND PURPOSE: A subset of patients with malignant glioma develops conspicuous lesions characterized by persistent restricted diffusion during treatment with bevacizumab. The purpose of the current study was to characterize the evolution of these lesions and to determine their relationship to patient outcome.

MATERIALS AND METHODS: Twenty patients with malignant glioma with persistent restricted-diffusion lesions undergoing treatment with bevacizumab were included in the current study. Mean ADC and the volume of restricted diffusion were computed for each patient during serial follow-up. Differences in TTP, TTS, and OS were compared between patients with restricted diffusion and matched controls by using Kaplan-Meier analysis with the logrank test and Cox hazard models.

RESULTS: Mean ADC values were generally stable with time (mean, 5.2 ± 12.6% change from baseline). The volume of restricted diffusion increased a median of 23% from baseline by 6 months. Patients with restricted-diffusion lesions had significantly greater TTP (logrank, P = .013), TTS (logrank, P = .008), and OS (logrank, P = .010) than matched controls. When available, advanced physiologic imaging of restricted-diffusion lesions showed hypovascularity on perfusion MR imaging and decreased amino acid uptake on 18F-FDOPA PET scans. Atypical gelatinous necrotic tissue was confirmed in the area of restricted diffusion in 1 patient.

CONCLUSIONS: Restricted-diffusion lesions in malignant gliomas treated with bevacizumab are generally stable with time and are associated with improved outcomes. These results combined with physiologic imaging and histopathologic data suggest that these lesions are not consistent with aggressive tumor.

ABBREVIATIONS: DSC = dynamic susceptibility contrast; ECAT HR = emission computed-assisted tomography high resolution; 18F-FDOPA = fluorine 18 fluorodopamine; Gd-DTPA = gadolinium diethylene triamine pentaacetic acid; KPS = Karnofsky Performance Scale; OS = overall survival; rCBV = relative cerebral blood volume; SEM = standard error of the mean; TTP = time to progression; TTS = time to survival from bevacizumab initiation; WHO = World Health Organization; VEGF = vascular endothelial growth factor

Malignant gliomas, which constitute two-thirds of the 20,500 primary brain malignancies diagnosed annually in the United States, typically progress despite treatment. The median survival after recurrence of WHO grade III gliomas (which include anaplastic astrocytomas, anaplastic oligoastrocytomas, and anaplastic oligodendrogliomas) is 39–40 weeks and 25–30 weeks for WHO grade IV gliomas (glioblastomas). Bevacizumab, a monoclonal antibody targeted against VEGF, is emerging as an alternative or complementary treatment in malignant gliomas. Because antiangiogenic treatment typically decreases the permeability of the blood-brain barrier, its therapeutic application reduces the value of contrast enhancement as a radiographic proxy for tumor response. Alternative MR imaging techniques such as DWI have shown promise in defining both tumor response and nonenhancing tumor progression in the setting of bevacizumab treatment.

ADC, a measure reflecting the magnitude of free water mobility obtained by using DWI, can be reduced by the presence of increased cell membranes that typify hypercellular tumor; however, ADC can be reduced by other biophysical parameters, including increased viscosity; protein content, such as occurs in abscess; and movement of water from the extracellular to intracellular space as seen in ischemia or cytotoxic edema. Recently, investigators and clinicians have
other studies suggest that these lesions represent chronic hypoxia and atypical gelatinous necrotic tissue.\textsuperscript{11,12}

The purpose of the current study was to determine the origin of these restricted-diffusion lesions by first characterizing the evolution of restricted-diffusion lesions in malignant gliomas treated with bevacizumab, examining these lesions in a subset of patients with advanced imaging findings and histopathology, and, last, determining the relationship of these lesions with patient outcomes including TTP, TTS, and OS.

Materials and Methods

Patient Selection

This retrospective study was granted a waiver of informed consent by our institutional review board, and all data collection was performed in compliance with Health Insurance Portability and Accountability Act regulations. Prospectively, 24 patients with malignant glioma who developed regions of well-demarcated high signal intensity on diffusion-weighted imaging that also corresponded to regions of reduced ADC values on surveillance imaging were identified by the senior author. Patients were screened for the diagnosis of malignant glioma (WHO grades III and IV), treatment with bevacizumab between January 2007 through August 2011, and a well-circumscribed lesion with restricted diffusion near the original tumor site that persisted for at least 2 months. Patients were required to be older than 18 years of age; have a history of surgical resection, temozolomide administration, and external beam radiation therapy; and have a baseline KPS \(\geq 70\) at diagnosis. Additional inclusion criteria were accurate reporting of recurrence status, absence of intracranial hemorrhage, and absence of clinical findings or observations of acute or subacute ischemia. Twenty cases were included in the study. As a control cohort, 60 patients with malignant glioma lacking conspicuous diffusion signal abnormality (both the well-circumscribed discrete lesions described above as well as any speckled diffuse pattern of diffusion restriction that can be seen in bevacizumab-treated patients) were collected from our neuro-oncology database. Controls were matched by sex, age, treatment (bevacizumab), tumor grade, and tumor histology at the time of bevacizumab treatment.

MR Diffusion Image Acquisition and Postprocessing Image Analysis

Patients were imaged on either a 1.5T or 3T clinical MR imaging system, with 50% of patients undergoing all studies on a 1.5T system and 50% of patients undergoing \(\leq 2\) studies on a 3T scanner and the rest of the studies on a 1.5T scanner (Avanto or Sonata, Siemens, Erlangen, Germany; HDx or LX, GE Healthcare, Milwaukee, Wisconsin) or a 3T scanner (Verio or Trio; Siemens). Anatomic sequences were collected according to standard clinical protocols and included axial precontrast T1-weighted, T2-weighted fast spin-echo, FLAIR, and postcontrast T1-weighted sequences. Diffusion-weighted images were acquired using a single-shot spin-echo sequence with a gradient-echo readout and a single-shot EPI readout, with several diffusion-encoding gradients placed along all three axes. The parameters were as follows: b = 1000 s/mm\(^2\), TR = 5000 ms, TE = 90 ms, 64 x 64 matrix, 20 diffusion-encoding directions, and 8 diffusion-encoding gradients. The diffusion measurements were made on an ROI that included the whole tumor and its surrounding tissue, with the exclusion of necrotic and nonviable areas.

Five patients had dynamic susceptibility perfusion imaging, performed following a preload dose (0.025 mmol/kg) of gadolinium contrast agent to diminish contrast leakage effects, followed by administration of a 3 to 5 mL/s bolus of Gd-DTPA at a dose of 10 to 20 mL (0.075 mmol/kg) followed by a 20 mL flush of isotonic saline by using a power injector. Parameters used included the following: TE ranging from 25 to 50 ms, TR ranging from 1250 to 1400 ms, flip angles ranging from 30° to 35°, 40–90 repetitions (temporal time points), sec thinning sections from 1 to 7 mm with intersection gap ranging from 0 to 1.5 mm, number of sections ranging from 6 to 20, and matrix size ranging from 80 x 96 to 128 x 128. Postprocessing data analysis was performed to determine standardized rCBV using previously published methods\textsuperscript{17} and commercially available software (IB Neuro v2.0, Imaging Biometrics, Elmgrove, Wisconsin).

\(123\)F-FDOPA PET images were obtained for 7 patients as previously described.\textsuperscript{18} A high-resolution full-ring ECAT HR or ECAT HR + PET scanner (CTI-Siemens, Knoxville, Tennessee) was used to acquire images, which contained either 47 contiguous transaxial sections with a section thickness of 3.4 mm (with the ECAT HR) or 63 contiguous transaxial sections with a section thickness of 2.4 mm (axial FOV of 15 cm with the ECAT HR +). After an intravenous injection of 3.5 mCi of \(123\)F-FDOPA, images were acquired immediately with 30-minute emission and 5-minute transmission scans.

Manual regions of interest contouring DWL-hyperintense lesions were obtained by a single observer and verified by 2 independent observers. Mean ADC within the region of interest and volume of the region of interest were extracted on each follow-up time point by using the Analysis of Functional NeuroImages software package (http://afni.nimh.nih.gov/afni). A single 2-mm-diameter circular region of interest was used to sample within the region of diffusion abnormality, and the minimum mean ADC value was recorded for all scan dates for each patient. For advanced imaging studies, color-coded rCBV perfusion maps, and \(123\)F-FDOPA PET scans were registered and compared with a \(b = 1000\) s/mm\(^2\) DWI obtained within 2 weeks of rCBV or \(123\)F-FDOPA PET image acquisition.

Statistical Analysis

An unpaired Student t-test was used to compare the mean ADC values across tumor grades. Linear regression was performed to define the trends in change in mean ADC values with time, and nonlinear regression was performed to define trends in the change in lesion volume with time. The comparison of the change in mean ADC with time and the change in the volume of restricted diffusion with time with survival outcomes was analyzed by using Kaplan-Meier analysis with a logrank test and Cox hazard models. Survival analysis comparing outcomes including TTP and TTS and OS from the initial diagnosis was performed to compare patients with controls.

Results

The demographic, clinical, and treatment characteristics of patients are shown in Table 1.
patients were stratified by scanner strength \((P = .998)\). Linear regression revealed that 13 patients (65%) had no significant change from baseline ADC values with time. Meanwhile, the lesion volume increased a median of 23.3% over baseline during the same 6-month period. Lesion volume remained stable in 18 patients (90%), with only 2 demonstrating a doubling of median lesion volume during 6 months. Regardless of whether diffusion signal abnormalities developed before or after bevacizumab treatment, lesions remained stable in size from the time of the first presentation to \(>1\) year afterward (Fig 2).

Localization of restricted-diffusion lesions near the ventricles and the corpus callosum was most common, because 19 lesions (95%) were adjacent to the ventricles and 11 lesions (55%) involved both the periventricular region and the corpus callosum. Additionally, 18 patients (80%) developed lesions that demonstrated faint spontaneous T1-weighted hyperintense rims. These T1 characteristics were visible for a year in all 9 patients (50%), with surveillance up to 1 year after lesion onset.

We next determined that the presence of restricted-diffusion lesions predicted improved survival outcomes. Patients with restricted-diffusion lesions had significantly greater TTP compared with matched controls (Fig 3; logrank, \(P = .013\)), with a median TTP of 248 days (95% confidence interval, 155–389 days) versus 159 days (95% confidence interval, 122–227 days), respectively. Similarly, patients with restricted-diffusion lesions had significantly greater TTS compared with matched controls (logrank, \(P = .008\)), demonstrating a median TTS of 596 days (95% confidence interval, 425–1395 days) versus 348 days (95% confidence interval, 257–390 days), respectively. Patients with restricted-diffusion lesions also had greater OS compared with matched controls (logrank, \(P = .010\)), illustrating a mean OS of 1676 days (95% confidence interval, 639–3141 days) versus 633 days (95% confidence interval, 559–765 days), respectively. While positive change in mean ADC with time trended toward longer TTP and TTS compared with stable or decreasing temporal changes in mean ADC, this was not statistically significant \((P = .15, \text{logrank}; P = .11, \text{logrank}, \text{respectively})\). Similarly, an increasing volume of restricted diffusion with time trended toward a shorter TTS compared with patients demonstrating stable or decreasing volume \((P = .08, \text{logrank})\).

In cases with advanced physiologic imaging, regions of diffusion signal abnormality were hypoperfused in 5 of 6 patients and showed decreased amino acid uptake on 18F-FDOPA PET scans in 7 of 8 patients (Fig 4). Examination of the nine 18F-FDOPA PET scans and 3 perfusion scans available for controls demonstrated avidity and hyperperfusion at the site of tumor in all patients. Recurrent tumor was found in the 6 controls with histology available (data not shown), and relapsing patients were noted an average of 232 days (SEM, 51.5 days) after bevacizumab treatment, and it persisted for 403 days (SEM, 98 days) from lesion onset. A quarter of patients developed restricted diffusion a mean of 55 ± 35 days before initiation of bevacizumab treatment (range, 1–84), with lesions lasting a mean of 409 days (SEM, 89) from lesion onset, with duration and evolution that was similar to those of the rest of the cohort (unpaired Student t test, \(P = .97\)). When we took all patients together, the restricted-diffusion lesions lasted a mean of 404 days (SEM, 76). Lesions developed in
tumor. Conversely, others have suggested that these persistent restricted-diffusion lesions may correspond to areas of atypical necrosis in the setting of anti-VEGF treatment-induced chronic hypoxia. In the current study, we have built on these previous observations by demonstrating that these lesions do not significantly change in the degree of restriction (ADC value) or volume of abnormality for up to 6 months after lesion onset following bevacizumab treatment. Thirteen patients (65%) did not demonstrate significant change of mean volume over this period.
Fig 3. Time to progression (A), time to survival (B), and overall survival (C) are calculated by using Kaplan-Meier curves to compare outcomes for patients with restricted-diffusion abnormalities with those for matched controls.

crosis. Most interesting, these lesions also illustrated a faint rim of spontaneous T1-weighted hyperintensity on precontrast images characteristic of necrosis. This hyperintensity was present in all cases of restricted-diffusion abnormalities and was observed within these restricted-diffusion lesions was lower than would be expected from viable biologic tissue. For example, 1 patient presented with restricted-diffusion abnormalities and a T2 remnant, which remained stable on follow-up. At the end of the study period, the patient had evidence of mass effect and demonstrated new restricted-diffusion abnormalities. Another patient demonstrated restricted-diffusion abnormalities in a previously exposed region, possibly indicating a new area of necrosis.
While most patients with recurrent malignant glioma with baseline local, diffuse, multifocal, or distant disease at recurrence later demonstrated the same patterns of tumor spread at the time of progression, correlating the different radiographic patterns of progression with histopathology and ADC values may provide insight into the distinction between diffusion signal abnormality associated with treatment effect and that associated with infiltrating tumor. In this study, the relatively slow changes in volume and mean ADC, the minimum ADC values that are much lower than is consistent with growing tumor, and the survival advantage in patients who develop persistent restricted-diffusion lesions, combined with the hypovascular and hypometabolic findings on perfusion MR imaging and $^{18}$F-FDOPA PET, respectively, are most compatible with nonviable tissue rather than active tumor.

Study Limitations
The variation within this small cohort of patients with respect to tumor histology, recurrence status at time of bevacizumab initiation, and treatment protocols before bevacizumab administration are potential limitations to the current study. Despite this heterogeneity, the presence of these lesions demonstrated a prolonged survival independent of histologic grade, recurrence status, and treatment history preceding bevacizumab administration. The frequency of MR follow-up imaging because resection was not included during their routine care at recurrence. Instead, advanced imaging correlates were used to corroborate the hypothesis that these lesions represent treatment effect rather than tumor progression. Additional histologic examinations of biopsies taken from the site of diffusion restriction are necessary to definitively clarify the etiology of these lesions. Because it is clear that these restricted-diffusion abnormalities may develop both in and outside the setting of bevacizumab treatment, a larger sample or pooling of cases across institutions is necessary to perform a more detailed characterization and segmentation of patients with this phenotype.

Conclusions

Imaging and survival data from the current study converge to further support the hypothesis that the development of geographic well-defined regions of persistent diffusion restriction after bevacizumab treatment in patients with malignant gliomas is not associated with growing tumor but rather may be related to atypical necrosis in many patients. Such lesions can be identified on the basis of a low minimum ADC value, atypical well-circumscribed appearance on T1-weighted MR images, and a characteristic location in paraventricular white matter regions.

References

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. *J Clin Oncol* 2010;28:e91–93


